Drug intelligence / Profile preview

phenylephrine + clonidine

Development stage
Unknown
Lead developer
Johnson & Johnson Consumer Inc. (J&JCI)
Modality
Small Molecules
Administration
Intravenous, Oral, Intranasal, Transdermal, Ophthalmic, Epidural, Intrathecal
01

Overview

Phenylephrine + clonidine is a combination of two small molecule drugs, each with distinct mechanisms of action. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that acts primarily as a vasoconstrictor, increasing blood pressure and reducing nasal congestion by constricting blood vessels[2][4]. Clonidine is an alpha-2 adrenergic receptor agonist that suppresses sympathetic outflow from the central nervous system, leading to reduced heart rate and lowered blood pressure[3][5][6]. This combination may be considered in certain clinical settings where both vasoconstriction (from phenylephrine) and central sympatholytic effects (from clonidine) are desired, such as perioperative management or specific cardiovascular indications. However, their concurrent use can result in complex hemodynamic interactions; for example, clonidine increases sensitivity to phenylephrine-induced vasoconstriction[8], while phenylephrine may antagonize the antihypertensive effect of clonidine[7]. There are no widely recognized brand names or fixed-dose products containing only this combination.

02

Targets

ADRA2C (α2C)ADRA2A (α2A)ADRA1A (α1A)ADRA1B (α1B)

Beyond the preview

Go deeper on phenylephrine + clonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenylephrine + clonidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call